Structural Elucidation of a Nonpeptidic Inhibitor Specific for the Human Immunoproteasome.
Cui, H., Baur, R., Le Chapelain, C., Dubiella, C., Heinemeyer, W., Huber, E.M., Groll, M.(2017) Chembiochem 18: 523-526
- PubMed: 28098422 
- DOI: https://doi.org/10.1002/cbic.201700021
- Primary Citation of Related Structures:  
5M2B - PubMed Abstract: 
Selective inhibition of the immunoproteasome is a promising approach towards the development of immunomodulatory drugs. Recently, a class of substituted thiazole compounds that combine a nonpeptidic scaffold with the absence of an electrophile was reported in a patent. Here, we investigated the mode of action of the lead compound by using a sophisticated chimeric yeast model of the human immunoproteasome for structural studies. The inhibitor adopts a unique orientation perpendicular to the β5i substrate-binding channel. Distinct interactions between the inhibitor and the subpockets of the human immunoproteasome account for its isotype selectivity.
Organizational Affiliation: 
Center for Integrated Protein Science Munich (CIPSM), Department of Chemistry, Technische Universität München, Lichtenbergstrasse 4, 85748, Garching, Germany.